Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

October 6, 2017: By Jon Swedien

legal issuesShire filed a lawsuit against Allergan on Oct. 2, alleging its competitor in the dry eye market has used an “anticompetitive scheme” to block or limit Xiidra’s entry into Medicare Part D prescription drug plans.

In the suit, Shire argues Allergan uses bundled discounts—which leverage Allergan’s glaucoma medications—as well as exclusive deals and other methods to keep Xiidra’s market share in Medicare Part D plans to 10 percent, compared with Restasis’ 90 percent. Conversely, Xiidra has achieved a 35 percent share in commercial drug plans since its US FDA approval in July 2016, according to Shire’s suit.

Allergan spokesman Mark Marmur told Reuters the lawsuit has no merit, and the company complies with Medicare procedures.

Shire filed the complaint in the US District Court of New Jersey.

In the complaint, Shire states one Medicare prescription drug plan told the company: “You could give [Xiidra] to us for free, and the numbers still wouldn’t work,” because of the bundled package Allergan offered.

Shire claims in the suit that patients can appeal for Xiidra when their plan only offers Restasis, but this increases their copays by two to five times.

In addition, Shire said that, when it has gotten Medicare plans to offer Xiidra, it’s often as a “non-preferred” item, which also increases copays by two to five times.

Shire argued that Allergan’s methods do not save patients any money because Restasis must often be used in conjunction with a topical prescription steroid, while Xiidra has the same list price as Restasis and does not require the use of any additional drugs.

Shire claimed that Allergan’s methods also hurt consumers because Restasis is approved to treat a limited subset of dry eye patients, while Xiidra is approved to treat all of the signs and symptoms of dry eye and can be prescribed to treat more patients.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Eylea Gains Approval in China for DME-Related Visual Impairment

Second Trial for Ophthalmic Industry Leader James Mazzo Ends in Hung Jury, Mistrial

Melgen Receives 17-Year Sentence for Medicare Fraud

NIH’s National Eye Institute Solicits Next-Generation Retina Organoids in $1 Million Prize Competition

Taiwan Liposome Company Registers for $50 Million IPO in US

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023